Charles M. Phillips

Internal Medicine

517 Moye Blvd
Greenville, NC 27834

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years.

Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years.

Journal: Annals of the rheumatic diseases

Published: March 14, 2026

Emergomyces canadensis: A rare cause of disseminated mycosis in North America.

Emergomyces canadensis: A rare cause of disseminated mycosis in North America.

Journal: JAAD case reports

Published: January 19, 2026

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.

Journal: RMD open

Published: May 08, 2025

A histopathological overlap of linear IgA bullous dermatosis and vasculitis.

A histopathological overlap of linear IgA bullous dermatosis and vasculitis.

Journal: JAAD case reports

Published: January 27, 2025

Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.

Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.

Journal: RMD open

Published: September 26, 2024

Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme.

Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme.

Journal: Journal of Crohn's & colitis

Published: November 09, 2023

Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.

Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.

Journal: Inflammatory bowel diseases

Published: August 08, 2022

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: April 21, 2022

Enoxaparin-Induced Hemorrhagic Bullae at Sites of Trauma and Endothelial Pathology.

Enoxaparin-Induced Hemorrhagic Bullae at Sites of Trauma and Endothelial Pathology.

Journal: Cutis

Published: November 30, 2021

I Do Not Like Green Eggs.

I Do Not Like Green Eggs.

Journal: Pediatric dermatology

Published: May 26, 2017

RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.

RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.

Journal: Experimental dermatology

Published: March 27, 2017

Parasitic Diseases With Cutaneous Manifestations.

Parasitic Diseases With Cutaneous Manifestations.

Journal: North Carolina medical journal

Published: September 14, 2016

Showing 1-12 of 17

Last Updated: 09/26/2026